SUPPLEMENT

Q1 2023 — Financial disclosures

Q1 2023PDF · 9 pages982 KB
Merck & Co., Inc.
Financial Highlights Package
First Quarter 2023
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q23........................3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q22.........................4
Table 3: Sales – Current Year and Prior Year by Quarter ...............5
Table 3a: Sales – U.S. / Ex- U.S. 1Q23.............................................6
Table 3b: Sales – Pharmaceutical Geographic Split .........................7
Table 4: Other (Income) Expense ....................................................8

-- 1 of 9 --

Sales 	14,487	$ 	15,901	$ 	-9%
Costs, Expenses and Other
Cost of sales 	3,926 	5,380 	-27%
Selling, general and administrative 	2,479 	2,323 	7%
Research and development 	4,276 	2,576 	66%
Restructuring costs 	67 	53 	26%
Other (income) expense, net 	89 	708 	-87%
Income Before Taxes 	3,650 	4,861 	-25%
Income Tax Provision 	825 	554
Net Income 	2,825 	4,307 	-34%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	(3)
Net Income Attributable to Merck & Co., Inc. 	2,821	$ 	4,310	$ 	-35%
Earnings per Common Share Assuming Dilution 	1.11	$ 	1.70	$ 	-35%
Average Shares Outstanding Assuming Dilution 	2,551 	2,537
Tax Rate 	22.6% 	11.4%
1Q22
GAAP
% Change
1Q23
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
1

-- 2 of 9 --

Sales 	14,487	$ 	15,901	$ 	14,593	$ 	14,959	$ 	13,830	$ 	59,283	$ 	-9%
Costs, Expenses and Other
Cost of sales 	3,926 	5,380 	4,216 	3,934 	3,881 	17,411 	-27%
Selling, general and administrative 	2,479 	2,323 	2,512 	2,520 	2,687 	10,042 	7%
Research and development 	4,276 	2,576 	2,798 	4,399 	3,775 	13,548 	66%
Restructuring costs 	67 	53 	142 	94 	49 	337 	26%
Other (income) expense, net 	89 	708 	438 	429 	(75) 	1,501 	-87%
Income Before Taxes 	3,650 	4,861 	4,487 	3,583 	3,513 	16,444 	-25%
Income Tax Provision 	825 	554 	538 	330 	495 	1,918
Net Income 	2,825 	4,307 	3,949 	3,253 	3,018 	14,526 	-34%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	(3) 	5 	5 	1 	7
Net Income Attributable to Merck & Co., Inc. 	2,821	$ 	4,310	$ 	3,944	$ 	3,248	$ 	3,017	$ 	14,519	$ 	-35%
Earnings per Common Share Assuming Dilution 1.11	$ 	1.70	$ 	1.55	$ 	1.28	$ 	1.18	$ 	5.71	$ 	-35%
Average Shares Outstanding Assuming Dilution 	2,551 	2,537 	2,540 	2,542 	2,548 	2,542
Tax Rate 	22.6% 	11.4% 	12.0% 	9.2% 	14.1% 	11.7%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
1Q
2023
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2022
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2

-- 3 of 9 --

First Quarter
Cost of sales 	3,926	$ 	545 	29 	574 	3,352	$
Selling, general and administrative 	2,479 	20 	1 	21 	2,458
Research and development 	4,276 	10 	10 	4,266
Restructuring costs 	67 	67 	67 	-
Other (income) expense, net 	89 	15 	(429) 	573 (3) 	159 	(70)
Income Before Taxes 	3,650 	(590) 	(97) 	429 	(573) 	(831) 	4,481
Income Tax Provision (Benefit) 	825 	(105) (4) 	(18) (4) 	95 (4) 	(60) (4) 	(88) 	913
Net Income 	2,825 	(485) 	(79) 	334 	(513) 	(743) 	3,568
Net Income Attributable to Merck & Co., Inc. 	2,821 	(485) 	(79) 	334 	(513) 	(743) 	3,564
Earnings per Common Share Assuming Dilution 	1.11	$ 	(0.19) 	(0.03) 	0.13 	(0.20) 	(0.29) 	1.40	$
Tax Rate 	22.6% 	20.4%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FIRST QUARTER 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax
income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs
related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, reflect a $37 million
loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty
income.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal	Certain Other Items
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
3

-- 4 of 9 --

First Quarter
Cost of sales 	5,380	$ 	680 	46 	726 	4,654	$
Selling, general and administrative 	2,323 	50 	21 	71 	2,252
Research and development 	2,576 	22 	7 	29 	2,547
Restructuring costs 	53 	- 	53 	53 	-
Other (income) expense, net 	708 	(115) 	684 	569 	139
Income Before Taxes 	4,861 	(637) 	(127) 	(684) 	(1,448) 	6,309
Income Tax Provision (Benefit) 	554 	(155) (3) 	(22) (3) 	(152) (3) 	(329) 	883
Net Income 	4,307 	(482) 	(105) 	(532) 	(1,119) 	5,426
Net Income Attributable to Merck & Co., Inc. 	4,310 	(482) 	(105) 	(532) 	(1,119) 	5,429
Earnings per Common Share Assuming Dilution 	1.70	$ 	(0.19) 	(0.04) 	(0.21) 	(0.44) 	2.14	$
Tax Rate 	11.4% 	14.0%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction
and certain other costs related to acquisitions and divestitures. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement
of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring
programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
FIRST QUARTER 2022 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Table 2b
4

-- 5 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2023 	2022 	1Q
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$14,487 	$15,901 	$14,593 	$14,959 	$13,830 	$59,283 	-9 	-5
PHARMACEUTICAL 	12,721 	14,107 	12,756 	12,963 	12,180 	52,005 	-10 	-6
Oncology
Keytruda 	5,795 	4,809 	5,252 	5,426 	5,450 	20,937 	20 	24
Alliance Revenue – Lynparza (2) 	275 	266 	275 	284 	292 	1,116 	3 	8
Alliance Revenue – Lenvima (2) 	232 	227 	231 	202 	216 	876 	2 	5
Alliance Revenue – Reblozyl (3) 	43 	52 	33 	39 	41 	166 	-19 	-19
Welireg 	42 	18 	27 	38 	40 	123 	128 	128
Vaccines (4)
Gardasil / Gardasil 9 	1,972 	1,460 	1,674 	2,294 	1,470 	6,897 	35 	43
ProQuad / M-M-R II / Varivax 	528 	470 	578 	668 	526 	2,241 	12 	14
RotaTeq 	297 	216 	173 	256 	139 	783 	38 	42
Vaxneuvance 	106 	5 	12 	16 	138 	170 	* 	*
Pneumovax 23 	96 	173 	153 	131 	145 	602 	-44 	-40
Vaqta 	40 	36 	35 	64 	39 	173 	12 	13
Hospital Acute Care
Bridion 	487 	395 	426 	423 	441 	1,685 	23 	27
Prevymis 	129 	94 	103 	114 	118 	428 	38 	44
Primaxin 	80 	58 	64 	63 	54 	239 	37 	48
Dificid 	65 	52 	66 	77 	67 	263 	25 	25
Noxafil 	60 	57 	60 	62 	58 	238 	5 	14
Zerbaxa 	50 	30 	46 	43 	49 	169 	66 	70
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	99 	72 	98 	88 	82 	341 	38 	38
Adempas (6) 	59 	61 	63 	57 	57 	238 	-3 	5
Virology
Lagevrio 	392 	3,247 	1,177 	436 	825 	5,684 	-88 	-87
Isentress / Isentress HD 	123 	158 	147 	161 	167 	633 	-23 	-20
Neuroscience
Belsomra 	56 	69 	69 	62 	59 	258 	-19 	-9
Immunology
Simponi 	180 	186 	181 	173 	166 	706 	-3 	2
Remicade 	51 	61 	53 	49 	44 	207 	-15 	-10
Diabetes (7)
Januvia 	551 	779 	756 	717 	561 	2,813 	-29 	-26
Janumet 	329 	454 	476 	417 	353 	1,700 	-28 	-24
Other Pharmaceutical (8) 	584 	602 	528 	603 	583 	2,319 	-3 	1
ANIMAL HEALTH 	1,491 	1,482 	1,467 	1,371 	1,230 	5,550 	1 	5
Livestock 	849 	832 	826 	829 	814 	3,300 	2 	8
Companion Animals 	642 	650 	641 	542 	416 	2,250 	-1 	2
Other Revenues (9) 	275 	312 	370 	625 	420 	1,728 	-12 	-22
*200% or greater
(7) Total Diabetes sales were $950 million in the first quarter of 2023 and $1,305 million in the first quarter of 2022.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed
products were $51 million in the first quarter of 2023 and $114 million in the first quarter of 2022.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $3,133 million in the first quarter of 2023 and $2,481 million in the first quarter of 2022.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of
sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
5

-- 6 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
1Q 2023 	1Q 2022 	% Change 	1Q 2023 	1Q 2022 	% Change 	1Q 2023 	1Q 2022 	% Change
TOTAL SALES (1) 	$14,487 	$15,901 	-9 	$6,659 	$7,339 	-9 	$7,828 	$8,563 	-9
PHARMACEUTICAL 	12,721 	14,107 	-10 	6,117 	6,773 	-10 	6,604 	7,334 	-10
Oncology
Keytruda 	5,795 	4,809 	20 	3,485 	2,779 	25 	2,310 	2,030 	14
Alliance Revenue – Lynparza (2) 	275 	266 	3 	142 	141 	1 	133 	125 	6
Alliance Revenue – Lenvima (2) 	232 	227 	2 	153 	156 	-2 	79 	71 	11
Alliance Revenue – Reblozyl (3) 	43 	52 	-19 	30 	27 	11 	12 	25 	-51
Welireg 	42 	18 	128 	41 	18 	122 	1 	-
Vaccines (4)
Gardasil / Gardasil 9 	1,972 	1,460 	35 	416 	418 	- 	1,556 	1,042 	49
ProQuad / M-M-R II / Varivax 	528 	470 	12 	421 	371 	14 	107 	99 	8
RotaTeq 	297 	216 	38 	180 	175 	3 	117 	41 	185
Vaxneuvance 	106 	5 	* 	94 	5 	* 	13 	*
Pneumovax 23 	96 	173 	-44 	40 	118 	-66 	56 	55 	2
Vaqta 	40 	36 	12 	30 	29 	4 	10 	7 	48
Hospital Acute Care
Bridion 	487 	395 	23 	276 	195 	41 	210 	199 	6
Prevymis 	129 	94 	38 	54 	40 	37 	75 	54 	39
Primaxin 	80 	58 	37 	4 	1 	* 	76 	58 	32
Dificid 	65 	52 	25 	62 	49 	25 	3 	3 	12
Noxafil 	60 	57 	5 	14 	10 	47 	46 	48 	-3
Zerbaxa 	50 	30 	66 	27 	18 	49 	23 	12 	92
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	99 	72 	38 	83 	71 	17 	16 	1 	*
Adempas (6) 	59 	61 	-3 	59 	61 	-3
Virology
Lagevrio 	392 	3,247 	-88 	-2 	1,523 	-100 	394 	1,723 	-77
Isentress / Isentress HD 	123 	158 	-23 	52 	61 	-16 	71 	97 	-27
Neuroscience
Belsomra 	56 	69 	-19 	16 	20 	-21 	40 	48 	-17
Immunology
Simponi 	180 	186 	-3 	180 	186 	-3
Remicade 	51 	61 	-15 	51 	61 	-15
Diabetes (7)
Januvia 	551 	779 	-29 	271 	325 	-17 	280 	454 	-38
Janumet 	329 	454 	-28 	56 	63 	-11 	272 	391 	-30
Other Pharmaceutical (8) 	584 	602 	-3 	172 	160 	8 	414 	443 	-7
ANIMAL HEALTH 	1,491 	1,482 	1 	482 	473 	2 	1,010 	1,009 	-
Livestock 	849 	832 	2 	174 	171 	2 	676 	660 	2
Companion Animals 	642 	650 	-1 	308 	302 	2 	334 	349 	-4
Other Revenues (9) 	275 	312 	-12 	60 	93 	-35 	214 	220 	-3
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $950 million in the first quarter of 2023 and $1,305 million in the first quarter of 2022.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$51 million in the first quarter of 2023 and $114 million in the first quarter of 2022.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $3,133 million in the first quarter of 2023 and $2,481 million in the first quarter of 2022.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
6

-- 7 of 9 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
2023 	2022 	% Change
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
TOTAL PHARMACEUTICAL 	$12,721 	$14,107 	$12,756 	$12,963 	$12,180 	$52,005 	-10
United States 	6,117 	6,773 	5,726 	6,620 	5,871 	24,989 	-10
% Pharmaceutical Sales 	48.1% 	48.0% 	44.9% 	51.1% 	48.2% 	48.1%
Europe (1) 	2,326 	3,309 	2,677 	2,427 	2,494 	10,906 	-30
% Pharmaceutical Sales 	18.3% 	23.5% 	21.0% 	18.7% 	20.5% 	21.0%
China 	1,694 	1,113 	1,355 	1,419 	1,216 	5,102 	52
% Pharmaceutical Sales 	13.3% 	7.9% 	10.6% 	10.9% 	10.0% 	9.8%
Japan 	737 	965 	1,092 	653 	832 	3,542 	-24
% Pharmaceutical Sales 	5.8% 	6.8% 	8.6% 	5.0% 	6.8% 	6.8%
Asia Pacific (other than China and Japan) 	703 	786 	854 	702 	691 	3,034 	-11
% Pharmaceutical Sales 	5.5% 	5.6% 	6.7% 	5.4% 	5.7% 	5.8%
Latin America 	470 	435 	453 	511 	472 	1,871 	8
% Pharmaceutical Sales 	3.7% 	3.1% 	3.6% 	3.9% 	3.9% 	3.6%
Eastern Europe/Middle East/Africa 	381 	450 	339 	360 	320 	1,469 	-15
% Pharmaceutical Sales 	3.0% 	3.2% 	2.7% 	2.8% 	2.6% 	2.8%
Canada 	141 	189 	166 	166 	158 	678 	-25
% Pharmaceutical Sales 	1.1% 	1.3% 	1.3% 	1.3% 	1.3% 	1.3%
Other 	152 	87 	94 	105 	126 	414 	75
% Pharmaceutical Sales 	1.2% 	0.6% 	0.6% 	0.9% 	1.0% 	0.8%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q23 	1Q22
Interest income 	(112)	$ 	(7)	$
Interest expense 	242 	243
Exchange losses 	61 	39
(Income) loss from investments in equity securities, net (1) (450) 	708
Net periodic defined benefit plan (credit) cost other than service cost 	(115) 	(121)
Other, net 	463 	(154)
Total 	89	$ 	708	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at
the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one
quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --